Trifluridine interactions
Full monograph for TrifluridineCheck it against another medicine
Medicines
41 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections…2 documented mechanisms | 12 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.2 documented mechanisms | 7 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.2 documented mechanisms | 13 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.2 documented mechanisms | 9 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections…2 documented mechanisms | 12 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of…2 documented mechanisms | 12 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections…2 documented mechanisms | 12 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to…2 documented mechanisms | 4 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Tofacitinib | Major | Others · Synergy | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.2 documented mechanisms | 2 sources — open the full entry |
| Upadacitinib | Major | Others · Synergy | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.2 documented mechanisms | 2 sources — open the full entry |
| Yellow Fever Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Azathioprine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections…2 documented mechanisms | 5 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…2 documented mechanisms | 15 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses…2 documented mechanisms | 18 sources — open the full entry |
| Chloramphenicol (Ophthalmic) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…2 documented mechanisms | 15 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…2 documented mechanisms | 15 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…2 documented mechanisms | 15 sources — open the full entry |
| Denosumab | Moderate | Synergy | Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections.2 documented mechanisms | 3 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…2 documented mechanisms | 15 sources — open the full entry |
| Diphtheria + Tetanus + Pertussis + Hepatitis B + Polio + HIB | Moderate | Antagonism · Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a…2 documented mechanisms | 21 sources — open the full entry |
| Diroximel Fumarate | Moderate | Synergy | The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may…2 documented mechanisms | 8 sources — open the full entry |
| Filgrastim | Moderate | Antagonism · Others | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given…2 documented mechanisms | 8 sources — open the full entry |
| Ganciclovir | Moderate | Synergy | The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or…2 documented mechanisms | 11 sources — open the full entry |
| Hepatitis B Vaccine [rDNA] | Moderate | Antagonism · Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a…2 documented mechanisms | 21 sources — open the full entry |
| Inactivated Hepatitis A vaccine | Moderate | Antagonism · Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a…2 documented mechanisms | 21 sources — open the full entry |
| Lactobacillus Rhamnosus GG | Moderate | Others | Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms… | 11 sources — open the full entry |
| Lamivudine + Zidovudine | Moderate | Antagonism | Coadministration with trifluridine may decrease the therapeutic effects of drugs that are substrates of thymidine kinase, such as zidovudine. The proposed…2 documented mechanisms | 7 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Moderate | Antagonism | Coadministration with trifluridine may decrease the therapeutic effects of drugs that are substrates of thymidine kinase, such as zidovudine. The proposed…2 documented mechanisms | 7 sources — open the full entry |
| Lenograstim | Moderate | Antagonism · Others | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given…2 documented mechanisms | 8 sources — open the full entry |
| Niraparib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib.2 documented mechanisms | 2 sources — open the full entry |
| Ocrelizumab | Moderate | Synergy | The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of…2 documented mechanisms | 2 sources — open the full entry |
| Olaparib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib.2 documented mechanisms | 5 sources — open the full entry |
| Pegfilgrastim [Pegylated Filgrastim] | Moderate | Antagonism · Others | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given…2 documented mechanisms | 4 sources — open the full entry |
| Roflumilast (Tablet) | Moderate | Others · Synergy | The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Roflumilast is a selective phosphodiesterase 4 (PDE4)…2 documented mechanisms | 7 sources — open the full entry |
| Tea Tree Oil + Geothermal Water + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses…2 documented mechanisms | 18 sources — open the full entry |
| Topotecan | Moderate | Synergy | The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects.2 documented mechanisms | 2 sources — open the full entry |
| Typhoid conjugate vaccine | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Typhoid polysaccharide vaccine | Moderate | Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 11 sources — open the full entry |
| Vitamin C + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses…2 documented mechanisms | 18 sources — open the full entry |
| Vitamin C + Vitamin E + Lutein + Copper + Zinc | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses…2 documented mechanisms | 18 sources — open the full entry |
This source documents no food, condition or duplication entries for Trifluridine.